ketamine has been researched along with Anxiety Neuroses in 29 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We previously reported that ketamine has anxiolytic effects in patients with treatment-resistant generalized anxiety and social anxiety disorders." | 9.34 | Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. ( Broughton, L; Glue, P; Le Nedelec, M; McNaughton, N; Medlicott, NJ; Neehoff, S; Sabadel, A; Shadli, S, 2020) |
| "In this maintenance treatment study, we sought to evaluate the effect on anxiety ratings, safety and tolerability of 3 months of weekly ketamine in 20 patients with treatment-refractory DSM IV generalised anxiety disorder (GAD) and/or social anxiety disorder (SAD), and subsequent assessment of remission post-treatment." | 9.27 | Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. ( Glue, P; Gray, A; Kibby, G; McNaughton, N; Medlicott, NJ; Neehoff, SM, 2018) |
| "The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder." | 9.24 | Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. ( Anderson-Fahey, B; Glue, P; Gray, A; Harland, S; Le Nedelec, M; McNaughton, N; Medlicott, NJ; Neehoff, S, 2017) |
| "Patients receiving ketamine for refractory depression and anxiety report dissociative symptoms in the first 60 min post-dose." | 9.24 | Effect of ketamine dose on self-rated dissociation in patients with treatment refractory anxiety disorders. ( Castle, C; Glue, P; Gray, A; Neehoff, S, 2017) |
| "Both anxious and non-anxious patients with bipolar depression had significant antidepressant responses to ketamine, although the anxious depressed group did not show a clear antidepressant response disadvantage over the non-anxious group." | 9.20 | A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. ( Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Zarate, CA, 2015) |
| "This review and consensus statement provides a general overview of the data on the use of ketamine for the treatment of mood disorders and highlights the limitations of the existing knowledge." | 8.95 | A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. ( Frye, MA; Mathew, SJ; McDonald, W; Nemeroff, CB; Sanacora, G; Schatzberg, AF; Summergrad, P; Turner, MS, 2017) |
| "Ketamine intravenous therapy (KIT) appears effective for treating depression in controlled trials testing a short series of infusions." | 8.31 | The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis. ( Heifets, BD; Hietamies, TM; Klise, AJ; Levine, SP; McInnes, LA; Qian, JJ; Williams, LM; Worley, MJ, 2023) |
| "Ketamine has emerged as a promising pharmacotherapy for depression and other mental illnesses, and the intramuscular (IM) administration of ketamine is now offered at many North American outpatient psychiatric clinics." | 8.12 | Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study. ( Ahuja, S; Brendle, M; Moore, C; Robison, R; Smart, L; Thielking, P, 2022) |
| "Ketamine has rapid anxiolytic effects in treatment-resistant obsessive compulsive, post-traumatic stress, generalised anxiety and social anxiety disorders." | 8.02 | Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. ( Glue, P; Gray, A; Neehoff, S; Nehoff, H; Truppman Lattie, D, 2021) |
| "This study included patients with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD) who were receiving intravenous (IV) ketamine treatment at a community-based clinic." | 8.02 | The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. ( Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LM; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, K, 2021) |
| "The aim of this study was to examine the effect on depressive symptoms of repeated subanesthetic doses of SC esketamine in unipolar and bipolar treatment-resistant depression (TRD) and clinical predictors of response." | 8.02 | Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity. ( Abdo, G; B Andreoli, S; B Puertas, C; Barbosa, M; Cohrs, FM; Del Porto, JA; Del Sant, LC; Delfino, R; Fava, VA; Lacerda, AL; Liberatori, A; Lucchese, AC; Magalhães, EJM; Nakahira, C; Sarin, LM; Steiglich, MS; Surjan, J; Tuena, MA, 2021) |
| "Ketamine is a noncompetitive antagonist of the N-methyl-d-aspartate (NMDA) glutamate receptor, which underlies its induction of pain relief and anaesthesia." | 6.82 | Ketamine treatment for refractory anxiety: A systematic review. ( Brooks, S; Dahlén, AD; Haggarty, CJ; Schiöth, HB; Tully, JL, 2022) |
| "Ketamine was not effective in facilitating avoidance extinction or in modifying LTP in WKY non-responders." | 5.48 | Ketamine facilitates extinction of avoidance behavior and enhances synaptic plasticity in a rat model of anxiety vulnerability: Implications for the pathophysiology and treatment of anxiety disorders. ( Fortress, AM; Pang, KCH; Smith, IM, 2018) |
| "Electronic databases were searched to capture randomised control trials measuring the anxiolytic effects of ketamine in contexts including mood disorders, anxiety disorders and chronic pain." | 5.41 | A transdiagnostic systematic review and meta-analysis of ketamine's anxiolytic effects. ( Alexander, L; Hartland, H; Jelen, LA; Mahdavi, K; Strawbridge, R; Young, AH, 2023) |
| "We previously reported that ketamine has anxiolytic effects in patients with treatment-resistant generalized anxiety and social anxiety disorders." | 5.34 | Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. ( Broughton, L; Glue, P; Le Nedelec, M; McNaughton, N; Medlicott, NJ; Neehoff, S; Sabadel, A; Shadli, S, 2020) |
| "To examine the effect of high baseline anxiety on response to ketamine versus midazolam (active placebo) in treatment-resistant depression (TRD)." | 5.30 | Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. ( Cusin, C; Debattista, C; Fava, M; Flynn, M; Freeman, MP; Hock, RS; Hoeppner, B; Ionescu, DF; Iosifescu, DV; Mathew, SJ; Papakostas, GI; Salloum, NC; Sanacora, G; Trivedi, MH, 2019) |
| "In this maintenance treatment study, we sought to evaluate the effect on anxiety ratings, safety and tolerability of 3 months of weekly ketamine in 20 patients with treatment-refractory DSM IV generalised anxiety disorder (GAD) and/or social anxiety disorder (SAD), and subsequent assessment of remission post-treatment." | 5.27 | Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. ( Glue, P; Gray, A; Kibby, G; McNaughton, N; Medlicott, NJ; Neehoff, SM, 2018) |
| "Patients receiving ketamine for refractory depression and anxiety report dissociative symptoms in the first 60 min post-dose." | 5.24 | Effect of ketamine dose on self-rated dissociation in patients with treatment refractory anxiety disorders. ( Castle, C; Glue, P; Gray, A; Neehoff, S, 2017) |
| "The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder." | 5.24 | Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. ( Anderson-Fahey, B; Glue, P; Gray, A; Harland, S; Le Nedelec, M; McNaughton, N; Medlicott, NJ; Neehoff, S, 2017) |
| "Both anxious and non-anxious patients with bipolar depression had significant antidepressant responses to ketamine, although the anxious depressed group did not show a clear antidepressant response disadvantage over the non-anxious group." | 5.20 | A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. ( Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Zarate, CA, 2015) |
| "This review and consensus statement provides a general overview of the data on the use of ketamine for the treatment of mood disorders and highlights the limitations of the existing knowledge." | 4.95 | A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. ( Frye, MA; Mathew, SJ; McDonald, W; Nemeroff, CB; Sanacora, G; Schatzberg, AF; Summergrad, P; Turner, MS, 2017) |
| " The reported effects of the use of mushrooms containing psilocybin by a number of cultures around the world has stimulated several trials showing beneficial effects of a single dose of psilocybin for over a year in healthy people, and for up to 3 months in patients with anxiety disorders who have advanced cancer." | 4.89 | Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin. ( Young, SN, 2013) |
| "Ketamine intravenous therapy (KIT) appears effective for treating depression in controlled trials testing a short series of infusions." | 4.31 | The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis. ( Heifets, BD; Hietamies, TM; Klise, AJ; Levine, SP; McInnes, LA; Qian, JJ; Williams, LM; Worley, MJ, 2023) |
| "Ketamine has emerged as a promising pharmacotherapy for depression and other mental illnesses, and the intramuscular (IM) administration of ketamine is now offered at many North American outpatient psychiatric clinics." | 4.12 | Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study. ( Ahuja, S; Brendle, M; Moore, C; Robison, R; Smart, L; Thielking, P, 2022) |
| "The aim of this study was to examine the effect on depressive symptoms of repeated subanesthetic doses of SC esketamine in unipolar and bipolar treatment-resistant depression (TRD) and clinical predictors of response." | 4.02 | Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity. ( Abdo, G; B Andreoli, S; B Puertas, C; Barbosa, M; Cohrs, FM; Del Porto, JA; Del Sant, LC; Delfino, R; Fava, VA; Lacerda, AL; Liberatori, A; Lucchese, AC; Magalhães, EJM; Nakahira, C; Sarin, LM; Steiglich, MS; Surjan, J; Tuena, MA, 2021) |
| "This study included patients with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD) who were receiving intravenous (IV) ketamine treatment at a community-based clinic." | 4.02 | The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. ( Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LM; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, K, 2021) |
| "Ketamine has rapid anxiolytic effects in treatment-resistant obsessive compulsive, post-traumatic stress, generalised anxiety and social anxiety disorders." | 4.02 | Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. ( Glue, P; Gray, A; Neehoff, S; Nehoff, H; Truppman Lattie, D, 2021) |
| " These behavioral effects are associated with i/ a reversal of anxiety and reduced self-care, ii/ a decrease in parenchymal cytokine production, iii/ a modulation of the microglial reactivity and iv/ a decrease in microglial quinolinic acid production that is correlated with plasmatic peripheral production." | 3.91 | Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine. ( Abdel-Ahad, P; Blatzer, M; Callebert, J; Chrétien, F; Danckaert, A; de Maricourt, P; De Medeiros, GF; Gaillard, R; Jouvion, G; Langeron, O; Launay, JM; Maignan, A; Petit, AC; Sharshar, T; Van Steenwinckel, J; Verdonk, F; Vinckier, F, 2019) |
| "Ketamine is a noncompetitive antagonist of the N-methyl-d-aspartate (NMDA) glutamate receptor, which underlies its induction of pain relief and anaesthesia." | 2.82 | Ketamine treatment for refractory anxiety: A systematic review. ( Brooks, S; Dahlén, AD; Haggarty, CJ; Schiöth, HB; Tully, JL, 2022) |
| "Twenty-six inpatients with treatment-resistant major depressive disorder (MDD) (DSM-IV criteria) received a single infusion of ketamine (0." | 2.79 | Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. ( Brutsche, NE; Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Slonena, EE; Vande Voort, JL; Zarate, CA, 2014) |
| "Ketamine has many properties that make it an interesting candidate for rapidly treating depression and anxiety in patients receiving hospice care." | 2.78 | Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. ( Carr, CH; Iglewicz, A; Irwin, SA; Lloyd, LS; Lo, JY; Nelesen, RA; Romero, SD, 2013) |
| " Ketamine is generally well tolerated by patients and has a limited side effect profile; however, the effects of long-term use are unknown." | 2.66 | Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature. ( Banov, MD; Dunn, T; Szabo, ST; Young, JR, 2020) |
| "Ketamine was not effective in facilitating avoidance extinction or in modifying LTP in WKY non-responders." | 1.48 | Ketamine facilitates extinction of avoidance behavior and enhances synaptic plasticity in a rat model of anxiety vulnerability: Implications for the pathophysiology and treatment of anxiety disorders. ( Fortress, AM; Pang, KCH; Smith, IM, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.45) | 29.6817 |
| 2010's | 14 (48.28) | 24.3611 |
| 2020's | 14 (48.28) | 2.80 |
| Authors | Studies |
|---|---|
| Tully, JL | 1 |
| Dahlén, AD | 1 |
| Haggarty, CJ | 1 |
| Schiöth, HB | 1 |
| Brooks, S | 1 |
| Ahuja, S | 1 |
| Brendle, M | 1 |
| Smart, L | 1 |
| Moore, C | 1 |
| Thielking, P | 1 |
| Robison, R | 1 |
| Hartland, H | 1 |
| Mahdavi, K | 1 |
| Jelen, LA | 1 |
| Strawbridge, R | 1 |
| Young, AH | 1 |
| Alexander, L | 1 |
| Hietamies, TM | 1 |
| McInnes, LA | 1 |
| Klise, AJ | 1 |
| Worley, MJ | 1 |
| Qian, JJ | 1 |
| Williams, LM | 1 |
| Heifets, BD | 1 |
| Levine, SP | 1 |
| Johnston, JN | 1 |
| Kadriu, B | 1 |
| Kraus, C | 1 |
| Henter, ID | 1 |
| Zarate, CA | 3 |
| Chen, Y | 1 |
| Yan, P | 1 |
| Wei, S | 1 |
| Zhu, Y | 1 |
| Lai, J | 1 |
| Zhou, Q | 1 |
| Glue, P | 5 |
| Neehoff, S | 4 |
| Sabadel, A | 1 |
| Broughton, L | 1 |
| Le Nedelec, M | 2 |
| Shadli, S | 1 |
| McNaughton, N | 3 |
| Medlicott, NJ | 3 |
| Truppman Lattie, D | 1 |
| Nehoff, H | 1 |
| Gray, A | 4 |
| Bilhimer, M | 1 |
| Hommer, K | 1 |
| Johnson, B | 1 |
| McIntyre, RS | 1 |
| Rodrigues, NB | 1 |
| Lipsitz, O | 1 |
| Nasri, F | 1 |
| Gill, H | 1 |
| Lui, LM | 1 |
| Subramaniapillai, M | 1 |
| Kratiuk, K | 1 |
| Teopiz, K | 1 |
| Ho, R | 1 |
| Lee, Y | 1 |
| Mansur, RB | 1 |
| Rosenblat, JD | 1 |
| Lucchese, AC | 1 |
| Sarin, LM | 1 |
| Magalhães, EJM | 1 |
| Del Sant, LC | 1 |
| B Puertas, C | 1 |
| Tuena, MA | 1 |
| Nakahira, C | 1 |
| Fava, VA | 1 |
| Delfino, R | 1 |
| Surjan, J | 1 |
| Steiglich, MS | 1 |
| Barbosa, M | 1 |
| Abdo, G | 1 |
| Cohrs, FM | 1 |
| Liberatori, A | 1 |
| Del Porto, JA | 1 |
| Lacerda, AL | 1 |
| B Andreoli, S | 1 |
| Chírico, MTT | 1 |
| Guedes, MR | 1 |
| Vieira, LG | 1 |
| Reis, TO | 1 |
| Dos Santos, AM | 1 |
| Souza, ABF | 1 |
| Ribeiro, IML | 1 |
| Noronha, SISR | 1 |
| Nogueira, KO | 1 |
| Oliveira, LAM | 1 |
| Gomes, FAR | 1 |
| Silva, FC | 1 |
| Chianca-Jr, DA | 1 |
| Bezerra, FS | 1 |
| de Menezes, RCA | 1 |
| Dogra, S | 1 |
| Conn, PJ | 1 |
| Harland, S | 1 |
| Anderson-Fahey, B | 1 |
| Castle, C | 1 |
| Neehoff, SM | 1 |
| Kibby, G | 1 |
| Fortress, AM | 1 |
| Smith, IM | 1 |
| Pang, KCH | 1 |
| Salloum, NC | 1 |
| Fava, M | 1 |
| Freeman, MP | 1 |
| Flynn, M | 1 |
| Hoeppner, B | 1 |
| Hock, RS | 1 |
| Cusin, C | 1 |
| Iosifescu, DV | 1 |
| Trivedi, MH | 1 |
| Sanacora, G | 2 |
| Mathew, SJ | 2 |
| Debattista, C | 1 |
| Ionescu, DF | 3 |
| Papakostas, GI | 1 |
| Verdonk, F | 1 |
| Petit, AC | 1 |
| Abdel-Ahad, P | 1 |
| Vinckier, F | 1 |
| Jouvion, G | 1 |
| de Maricourt, P | 1 |
| De Medeiros, GF | 1 |
| Danckaert, A | 1 |
| Van Steenwinckel, J | 1 |
| Blatzer, M | 1 |
| Maignan, A | 1 |
| Langeron, O | 1 |
| Sharshar, T | 1 |
| Callebert, J | 1 |
| Launay, JM | 1 |
| Chrétien, F | 1 |
| Gaillard, R | 1 |
| Banov, MD | 1 |
| Young, JR | 1 |
| Dunn, T | 1 |
| Szabo, ST | 1 |
| Post, RM | 1 |
| Yatham, LN | 1 |
| Vieta, E | 1 |
| Berk, M | 1 |
| Nierenberg, AA | 1 |
| Irwin, SA | 1 |
| Iglewicz, A | 1 |
| Nelesen, RA | 1 |
| Lo, JY | 1 |
| Carr, CH | 1 |
| Romero, SD | 1 |
| Lloyd, LS | 1 |
| Tang, WK | 1 |
| Morgan, CJ | 1 |
| Lau, GC | 1 |
| Liang, HJ | 1 |
| Tang, A | 1 |
| Ungvari, GS | 1 |
| Luckenbaugh, DA | 2 |
| Niciu, MJ | 2 |
| Richards, EM | 2 |
| Slonena, EE | 1 |
| Vande Voort, JL | 1 |
| Brutsche, NE | 1 |
| Ray, SM | 1 |
| Kious, BM | 1 |
| Frye, MA | 1 |
| McDonald, W | 1 |
| Turner, MS | 1 |
| Schatzberg, AF | 1 |
| Summergrad, P | 1 |
| Nemeroff, CB | 1 |
| Young, SN | 1 |
| Tellier, PP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Music as a Potential Intervention to Improve Hemodynamic Tolerability of Repetitive Sub-Anesthetic IV Ketamine Infusions in Bipolar and Unipolar Depression: A Pilot Study[NCT04701866] | 32 participants (Actual) | Interventional | 2021-01-11 | Completed | |||
| Ketamine Infusion for Social Anxiety Disorder[NCT02083926] | Early Phase 1 | 18 participants (Actual) | Interventional | 2015-01-02 | Completed | ||
| Prediction of the Therapeutic Response in Depression Based on an Early Neuro-computational Modeling Assessment of Motivation[NCT05866575] | 136 participants (Anticipated) | Interventional | 2023-06-01 | Not yet recruiting | |||
| A Prospective Randomized Controlled Trial of Electroconvulsive Therapy With Ketamine Anesthesia (Standard Therapy) and High Intensity Ketamine With Electroconvulsive Therapy Rescue for Treatment-Resistant Depression - EAST HIKER Trial[NCT03272698] | Phase 4 | 62 participants (Anticipated) | Interventional | 2017-09-01 | Recruiting | ||
| Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-05-01 | Not yet recruiting | ||
| Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist[NCT00088699] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2004-07-26 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinician-administered scale for the assessment of fear and avoidance found in social phobia (SAD); it has 24 items divided into 2 subscales, 13 for performance anxiety, and 11 for social situations each rated from 0 to 3 (0=none,1=mild,2=moderate,3=definite). The sum scores for Fear and Avoidance results in an overall score (max 144 points). There are 4 clinician subscales: fear of social interaction, fear of performance, avoidance of social interaction and avoidance of performance 0 to 30= SAD is unlikely 30 to 60=SAD is probable 60 to 90=SADis very probable >90= SAD highly probable (NCT02083926)
Timeframe: Day 1 (1+28)
| Intervention | score on a scale (Mean) |
|---|---|
| Ketamine Infusion on Day 0 or Day 28 | 66.1 |
| Saline Infusion on Day 0 or Day 28 | 86.1 |
"Instrument that tries to measure anxiety, that is believed to range across a continuum of values and cannot easily be directly measured.We used a straight horizontal line of 100 mm in length. The ends were defined as the extreme limits of the parameter to be measured (anxiety); oriented from the left (no anxiety) to the right (worst anxiety ever felt). The patient marks on the line the point that they feel represents their perception of their current state.The VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the patient marks.~We examined Visual Analog Scale (VAS) for anxiety symptoms at screening, 1 hour prior to infusion, 1, 2 and 3 hours after infusion, 1, 2, 3, 5, 7, 10, and 14 days following a single ketamine/saline infusion." (NCT02083926)
Timeframe: Day 1 (1+28)
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine Infusion on Day 0 or Day 28 | 12.1 |
| Saline Infusion on Day 0 or Day 28 | 19.6 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 1.17 |
| Placebo - Healthy Volunteers | 1.48 |
| Ketamine - MDD Patients | 33.83 |
| Placebo - MDD Patients | 31.82 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 2.45 |
| Placebo - Healthy Volunteers | 0.67 |
| Ketamine - MDD Patients | 23.73 |
| Placebo - MDD Patients | 30.68 |
9 reviews available for ketamine and Anxiety Neuroses
| Article | Year |
|---|---|
Ketamine treatment for refractory anxiety: A systematic review.
Topics: Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Humans; Ketamine; Receptors, N-Methyl-D-Aspartate | 2022 |
A transdiagnostic systematic review and meta-analysis of ketamine's anxiolytic effects.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Depression; Humans; Ketamine; Mood Disorders | 2023 |
Ketamine in neuropsychiatric disorders: an update.
Topics: Anhedonia; Antidepressive Agents; Anxiety Disorders; Bipolar Disorder; Depression; Humans; Ketamine | 2024 |
Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.
Topics: Allosteric Regulation; Animals; Anxiety Disorders; Brain; Depressive Disorder, Major; Depressive Dis | 2021 |
Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Bipolar Disorder; Humans; Ketamine; Stress Disorders, Post-T | 2020 |
Beyond evidence-based treatment of bipolar disorder: Rational pragmatic approaches to management.
Topics: Ankyrins; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Anxiety Disorders; Bipolar Disord | 2019 |
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.
Topics: Anxiety Disorders; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Evide | 2017 |
Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin.
Topics: Affect; Anesthetics, Dissociative; Animals; Anti-Anxiety Agents; Anti-Dyskinesia Agents; Anxiety Dis | 2013 |
Club drugs: is it all ecstasy?
Topics: Adolescent; Adolescent Behavior; Anxiety Disorders; Humans; Illicit Drugs; Ketamine; Methamphetamine | 2002 |
8 trials available for ketamine and Anxiety Neuroses
| Article | Year |
|---|---|
Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Blood Pressure; Brain-Derived Neuro | 2020 |
Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; Depression; Depressiv | 2017 |
Effect of ketamine dose on self-rated dissociation in patients with treatment refractory anxiety disorders.
Topics: Adolescent; Anxiety; Anxiety Disorders; Dissociative Disorders; Double-Blind Method; Humans; Ketamin | 2017 |
Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Drug Resistance; Female; Humans; In | 2018 |
Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression.
Topics: Adult; Anxiety; Anxiety Disorders; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2019 |
Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Anxiety Agents; Ant | 2013 |
Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Anxiety Agents; Ant | 2013 |
Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Anxiety Agents; Ant | 2013 |
Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Anxiety Agents; Ant | 2013 |
Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
Topics: Antidepressive Agents; Anxiety Disorders; Depressive Disorder, Major; Depressive Disorder, Treatment | 2014 |
A single infusion of ketamine improves depression scores in patients with anxious bipolar depression.
Topics: Adult; Affect; Anxiety; Anxiety Disorders; Bipolar Disorder; Cross-Over Studies; Depression; Double- | 2015 |
12 other studies available for ketamine and Anxiety Neuroses
| Article | Year |
|---|---|
Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study.
Topics: Adult; Anxiety; Anxiety Disorders; Cohort Studies; Depression; Depressive Disorder, Major; Humans; K | 2022 |
The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis.
Topics: Anxiety; Anxiety Disorders; Depression; Humans; Ketamine; Retrospective Studies | 2023 |
Ketamine metabolite alleviates morphine withdrawal-induced anxiety via modulating nucleus accumbens parvalbumin neurons in male mice.
Topics: Analgesics, Opioid; Animals; Anxiety; Anxiety Disorders; Ketamine; Male; Mice; Morphine; Neurons; Nu | 2023 |
Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale.
Topics: Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Double-Blind Method; Fear; Female; Humans; Ketamine | 2021 |
Comments on Medication Safety in the Emergency Department After a Trip to the K-Hole.
Topics: Anxiety Disorders; Emergency Service, Hospital; Humans; Ketamine; Medication Errors | 2020 |
The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Administration, Intravenous; Adult; Anxiety; Anxiety Disorders; Bipolar Disorder; Canada; Depressive | 2021 |
Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity.
Topics: Adult; Antidepressive Agents; Anxiety; Anxiety Disorders; Comorbidity; Depression; Depressive Disord | 2021 |
Lasting effects of ketamine and isoflurane administration on anxiety- and panic-like behavioral responses in Wistar rats.
Topics: Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anxiety Disorders; Behavior, Animal; Is | 2021 |
Ketamine facilitates extinction of avoidance behavior and enhances synaptic plasticity in a rat model of anxiety vulnerability: Implications for the pathophysiology and treatment of anxiety disorders.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Avoidance Learning; Extinction, Psychological; Gene | 2018 |
Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine.
Topics: Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Biomarkers, Pharmacological; Depression; | 2019 |
Psychiatric morbidity in ketamine users attending counselling and youth outreach services.
Topics: Adolescent; Adult; Anxiety Disorders; Comorbidity; Counseling; Depressive Disorder; Excitatory Amino | 2015 |
Sustained Resolution of Panic Disorder, Agoraphobia, and Generalized Anxiety Disorder With a Single Ketamine Infusion: A Case Report.
Topics: Adult; Agoraphobia; Anxiety Disorders; Depressive Disorder, Major; Female; Humans; Ketamine; Panic D | 2016 |